Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lowered its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 37.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 248,846 shares of the medical technology company's stock after selling 150,000 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.18% of Alphatec worth $2,284,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Barclays PLC grew its position in Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after buying an additional 133,653 shares during the period. Courier Capital LLC boosted its stake in shares of Alphatec by 76.9% during the 4th quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company's stock worth $633,000 after acquiring an additional 30,000 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of Alphatec during the 4th quarter valued at $120,000. Nisa Investment Advisors LLC increased its stake in shares of Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new position in Alphatec in the 4th quarter worth $152,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Wall Street Analyst Weigh In

ATEC has been the subject of a number of analyst reports. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Piper Sandler restated an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Alphatec currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.89.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles sold 32,393 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77. Following the completion of the sale, the chief executive officer now directly owns 5,940,391 shares of the company's stock, valued at approximately $64,690,857.99. This represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 12,946 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58. Following the transaction, the executive vice president now owns 722,128 shares of the company's stock, valued at approximately $7,748,433.44. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 126,945 shares of company stock valued at $1,416,352 in the last quarter. 20.90% of the stock is owned by insiders.

Alphatec Trading Up 2.8%

Shares of Alphatec stock traded up $0.34 on Monday, reaching $12.55. The company had a trading volume of 218,526 shares, compared to its average volume of 2,110,072. The firm's 50-day moving average price is $10.50 and its two-hundred day moving average price is $10.16. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $12.82. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -9.80 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company's revenue was up 22.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.34) EPS. As a group, research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.